| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -49,501 | -22,826 |
| Depreciation expense | 1,113 | 743 |
| Stock-based compensation expense | 1,978 | 1,356 |
| Change in fair value of the convertible loan | 15,191 | 548 |
| Non-cash interest expense | 11,739 | 7,398 |
| Change in right-of-use asset | -1,770 | -1,183 |
| Prepaid expenses and other assets | 155 | 1,173 |
| Accounts payable and accrued liabilities | -24 | -818 |
| Accrued compensation | -437 | -696 |
| Operating lease liability | -763 | -506 |
| Net cash used in operating activities | -19,089 | -14,791 |
| Purchases of property and equipment | 490 | 248 |
| Net cash used in investing activities | -490 | -248 |
| Proceeds from issuance of term debt, net of issuance costs | 25,000 | 10,000 |
| Payments for taxes related to net share settlement of equity awards | 46 | 14 |
| Net cash provided by financing activities | 24,954 | 9,986 |
| Net increase in cash, cash equivalents and restricted cash | 5,375 | -5,053 |
| Cash and cash equivalents at beginning of period | 14,771 | - |
| Cash and cash equivalents at end of period | 20,146 | - |
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)